UniProtKB/Swiss-Prot P01008: Variant p.Cys160Tyr

Antithrombin-III
Gene: SERPINC1
Chromosomal location: 1q23-q25.1
Variant information

Variant position:  160
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Cysteine (C) to Tyrosine (Y) at position 160 (C160Y, p.Cys160Tyr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (C) to large size and aromatic (Y)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In AT3D; type-I.
Any additional useful information about the variant.



Sequence information

Variant position:  160
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  464
The length of the canonical sequence.

Location on the sequence:   FDTISEKTSDQIHFFFAKLN  C RLYRKANKSSKLVSANRLFG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFG

Mouse                         FDTISEKTSDQIHFFFAKLNCRLYRKANKSSDLVSANRLFG

Bovine                        FDTISEKTSDQIHFFFAKLNCRLYRKANKSSELVSANRLFG

Sheep                         FDTISEKTSDQIHFFFAKLNCRLYRKANKSSELVSANRLFG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 33 – 464 Antithrombin-III
Binding site 161 – 161 Heparin
Binding site 177 – 177 Heparin
Glycosylation 167 – 167 N-linked (GlcNAc...)
Disulfide bond 40 – 160
Helix 151 – 166


Literature citations

Antithrombin mutation database: 2nd (1997) update.
Lane D.A.; Bayston T.; Olds R.J.; Fitches A.C.; Cooper D.N.; Millar D.S.; Jochmans K.; Perry D.J.; Okajima K.; Thein S.L.; Emmerich J.;
Thromb. Haemost. 77:197-211(1997)
Cited for: VARIANTS AT3D SER-17; PRO-23; ASN-39; CYS-56; LEU-73; CYS-79; HIS-79; SER-79; ASN-87 DEL; CYS-89; LEU-90; CYS-95; SER-95; PRO-98; THR-112; PHE-131; VAL-131; LYS-133; PHE-138-139-LYS DEL; PRO-148; PRO-150; PRO-158; TYR-160; GLN-161; CYS-198; HIS-198; ILE-218 DEL; ASP-219; LYS-219; ARG-257; LYS-269; ILE-283; ASN-316; LYS-334; ARG-412; THR-414; PRO-416; SER-416; VAL-419; ASP-424; CYS-425; HIS-425; PRO-425; LEU-426; CYS-434; LEU-434; SER-434; THR-436; LYS-437; GLY-438; MET-438; LEU-439; THR-439; THR-453; ARG-456; THR-457; ASP-459; LEU-461 AND PHE-462; VARIANTS GLU-30; THR-52 AND CYS-190;

Three novel mutations of antithrombin inducing high-molecular-mass compounds.
Emmerich J.; Vidaud D.; Alhenc-Gelas M.; Chadeuf G.; Gouault-Heilmann M.; Aillaud M.-F.; Aiach M.;
Arterioscler. Thromb. 14:1958-1965(1994)
Cited for: VARIANTS AT3D HIS-79 AND TYR-160;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.